Adimab
PrivateLast Round
Secondary
Feb 6, 2015
Est. Valuation
$1.1B
Total Funding Raised
$39.18M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Adimab is a biotechnology company that provides a proprietary yeast-based platform for the discovery, maturation, and engineering of therapeutic human antibodies for pharmaceutical and biotechnology partners.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adimab Comparables
Compare Adimab with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera | 84% | |
| Alloy Therapeutics | 82% | |
| OmniAb Inc. | 81% |
Adimab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Secondary | Feb 6, 2015 | ||||
| Series F | Apr 3, 2012 | ||||
| Series E | Nov 22, 2010 | ||||
| Series D | Oct 1, 2009 | ||||
| Series C | Nov 21, 2008 | ||||
Series B | Mar 25, 2008 |
Key People
Founding team and executive leadership
Adimab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series C, Series D, Series F, Series E, Series A, Series B |
| GV | Series F, Series E, Series D |
| InterWest Partners | Series C |
| Fidelity Management & Research Company | Secondary |
| OrbiMed | Series C, Series D, Series F, Series E |
| Endeavor Venture Funds | Series C |
| Fidelity Investments | Secondary |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 133% MoM, reaching 7.6K.
- Mar 18, 2026
Therapeutic candidate completed Phase 1a trial with partner Gates MRI.
Adimab Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Adimab's valuation, stock price, and market status.
Is Adimab a public or private company?
Adimab is a private company.
What is the current stock price of Adimab?
Adimab is a private company with no public stock price. No recent secondary market data is available.
How much is Adimab worth (valuation)?
Adimab's valuation is estimated at $1.1B based on funding round data.
Can I buy Adimab stock?
Adimab shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Adimab's last funding round?
Adimab's most recent funding round was Secondary on February 6, 2015.
Who are the main investors in Adimab?
Key investors in Adimab include SV Health Investors, GV, Polaris Partners.
Will Adimab IPO soon?
No public IPO plans have been announced for Adimab.
How can I track Adimab secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Adimab's secondary market activity and sign up for updates.